European Growth Stocks Insiders Are Investing In
As European markets navigate volatility driven by escalating Middle East tensions and fluctuating energy prices, investors are closely monitoring opportunities in growth stocks that show resilience amid inflation concerns. In this environment, companies with high insider ownership can be particularly appealing, as they often signal strong internal confidence and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.8% |
| MilDef Group (OM:MILDEF) | 10.3% | 32.5% |
| KebNi (OM:KEBNI B) | 16.3% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 54.8% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 55.6% |
| CD Projekt Red (WSE:CDR) | 35.2% | 50.1% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 29.8% |
Let's explore several standout options from the results in the screener.
Ambu (CPSE:AMBU B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ambu A/S, along with its subsidiaries, is engaged in the research, development, manufacturing, marketing, and sale of medical technology solutions across North America, Europe, and other international markets; it has a market cap of DKK16.99 billion.
Operations: Ambu's revenue primarily comes from its Medical Technology Solutions segment, which generated DKK6.24 billion.
Insider Ownership: 20.5%
Earnings Growth Forecast: 21.5% p.a.
Ambu's recent earnings report shows solid growth, with Q3 2026 sales reaching DKK 1.64 billion, up from DKK 1.51 billion the previous year, and net income rising to DKK 156 million. Despite a volatile share price recently, Ambu is expected to achieve significant annual earnings growth of over 20% in the coming years, outpacing the Danish market average. The company's revenue is also projected to grow faster than the market at an annual rate of 10.5%.
- Click to explore a detailed breakdown of our findings in Ambu's earnings growth report.
- The valuation report we've compiled suggests that Ambu's current price could be inflated.
Basic-Fit (ENXTAM:BFIT)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Basic-Fit N.V. operates and franchises fitness clubs across multiple European countries under the Basic-Fit brand, with a market cap of €2.05 billion.
Operations: The company generates revenue primarily from its operations in the Benelux region (€581.70 million) and from its activities in France, Spain, and Germany (€920.20 million).
Insider Ownership: 12%
Earnings Growth Forecast: 33% p.a.
Basic-Fit's recent earnings report highlights a turnaround, with half-year sales of €800.3 million and net income of €23.1 million, compared to a loss last year. Analysts forecast significant annual earnings growth of 33%, outpacing the Dutch market's 17.3%. However, revenue growth is expected to lag behind the market at 9.8% annually. The stock trades below analyst price targets and fair value estimates but faces challenges with interest coverage from earnings.
- Click here and access our complete growth analysis report to understand the dynamics of Basic-Fit.
- Insights from our recent valuation report point to the potential undervaluation of Basic-Fit shares in the market.
Bonesupport Holding (OM:BONEX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across the United States, Europe, and internationally, with a market cap of SEK14.03 billion.
Operations: The company generates revenue primarily from its Pharmaceuticals segment, which amounted to SEK1.29 billion.
Insider Ownership: 10.6%
Earnings Growth Forecast: 32.2% p.a.
Bonesupport Holding's strong insider ownership aligns with its impressive growth prospects, as earnings are forecast to grow significantly at 32.2% annually, outpacing the Swedish market. The company recently announced a pivotal study published in NEJM demonstrating reduced systemic antibiotic use without compromising outcomes, which could transform orthopedic infection management. With substantial insider buying and trading below estimated fair value, Bonesupport is poised for notable regional expansion through new distribution partnerships in Australia and New Zealand.
- Delve into the full analysis future growth report here for a deeper understanding of Bonesupport Holding.
- Our comprehensive valuation report raises the possibility that Bonesupport Holding is priced higher than what may be justified by its financials.
Seize The Opportunity
- Unlock our comprehensive list of 214 Fast Growing European Companies With High Insider Ownership by clicking here.
- Searching for a Fresh Perspective? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com